View more in

Durable Responses Found With Teclistamab in Relapsed or Refractory Multiple Myeloma

Cover picture for the articlePatients taking teclistamab for relapsed or refractory multiple myeloma saw durable response, and a well-tolerated toxicity profile. Teclistamab was well tolerated and showed durable responses that depended over time in patients with relapsed or refractory multiple myeloma treated on the phase 1 MajesTec-1 study (NCT03145181), according to a study published in The Lancet.

Comments / 1

Comments / 0